news
Inflation/cost of goods major concerns for pharma manufacturing
Pharma industry calls for support as restrictive pricing measures and rising costs of goods/inflation could undermine the availability of medicines.
List view / Grid view
Manufacturing
news
Ensuring content uniformity for HPAPI products
Here, EPR discusses critical considerations to ensure content uniformity in HPAPI drugs produced using dry techniques.
whitepaper
Article: Outsourcing biologics: key considerations
PCI’s Tim Roberts discusses key factors when outsourcing the clinical and commercial supply of biologics, and what makes a strong CDMO partnership.
news
HPAPI market to value $27bn by 2025
Driven by oncology drug demand, the highly potent active pharmaceutical ingredients (HPAPIs) market is anticipated to grow by $7bn in three years.
news
Could process data offer a different approach for predicting quality?
A data collection study provides a product quality dataset that could form the basis of advanced analytical models to predict final product quality.
whitepaper
Case study: Reduce plate counts with rapid microbial monitoring
Find out how a pharma company maintained product quality and reduced plate counts by 25 percent using a rapid microbial monitoring analyser – the 7000RMS.
news
Update on setting occupational exposure limits
Here, EPR summarises a recent review, outlining the critical considerations when setting occupational exposure limits (OELs), with a focus on HPAPIs.
news
Northern Ireland’s drug development industry worth £2.4 billion
Recent ABPI figures show Northern Ireland’s life sciences sector supports 19,500 jobs directly, 15,000 jobs indirectly and is worth £2.4 billion.
whitepaper
ebook: Proactive clinical supply planning
The importance of thoroughly planned resupply strategies in maintaining clinical supply inventories as studies move into late phase.
whitepaper
Article: Clinical and commercial outsourcing
The demand for biologics and high potent medicines is forcing the industry to consider alternatives, such as outsourcing and integrated solutions.
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-300x278.jpg)
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-e1629971959212.jpg)
news
Lilly to build two new US manufacturing sites
Eli Lilly and Company announces plans to establish two new manufacturing facilities in Indiana USA worth $2.1 billion.
news
Collaboration between Lonza and IBF to progress Israeli biologics sector
Israel Biotech Fund (IBF) and Lonza announce agreement to accelerate the development and manufacture of Israeli biologics and small molecules.
news
Mitigating the risks of PPE shortages for compounding pharmacies
Personal protective equipment (PPE) is a critical aspect of environmental and contamination control for compounding facilities, here we look at strategies to overcome PPE shortages.
news
Bavarian Nordic signs supply contract for smallpox vaccine as monkeypox cases rise
The agreement between Bavarian Nordic and an undisclosed country aims to ensure sufficient supply of smallpox vaccine to meet the country’s requirements for vaccinating individuals at risk for monkeypox.
podcasts
EPR Podcast Episode 11 – Developing vaccine technologies – Giulia Giordano and Mark Doherty, GSK
Why is vaccine manufacturing becoming more biological? How could Generalized Modules for Membrane Antigens (GMMA) enhance vaccinology? What developments have there been in adjuvant systems? Discover all this and more in this podcast with GSK experts.
